The Pharma Data

MARCH 22, 2023

Sandoz has more than two decades of experience researching, developing and bringing biosimilars to markets across the globe. 1 About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company.

FDA Approval 40

FDA Approval Generic Pharmaceutical Medicine Protein 40

The Pharma Data

MARCH 15, 2022

“Today’s approval of the first generic for one of the most commonly prescribed complex drug-device combination products to treat asthma and COPD is another step forward in our commitment to bring generic copies of complex drugs to the market, which can improve quality of life and help reduce the cost of treatment,” said Sally Choe, Ph.D.,

FDA Approval 52

FDA Approval Generic Drugs Production Drugs 52

The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. Nor can there be any guarantee that such products will be commercially successful in the future. About Sandoz.

Clinical Development 52

Clinical Development Medicine Development Containment 52

The Pharma Data

OCTOBER 26, 2021

Sandoz is a global leader in generic pharmaceuticals and biosimilars. Its global portfolio covers all major therapeutic areas with a global market leadership position in biosimilars, generic antibiotics and oncology medicines. About 108,000 people of more than 140 nationalities work at Novartis around the world.

Medicine 52

Medicine Sales Marketing Generic Pharmaceutical 52

The Pharma Data

MAY 15, 2023

Huebscher , non-executive board member in companies, institutions and former CEO of Solvias Group, a Swiss contract research firm, which she led between 2014 and 2021. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. The new board members are: Dr. Karen J.

Sales 40

Sales Production Doctors Doctor 40

The Pharma Data

MAY 18, 2021

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. Nor can there be any guarantee that such products will be commercially successful in the future. About Sandoz.

Manufacturing 40

Manufacturing Production Containment Generic Pharmaceutical 40

The Pharma Data

MAY 2, 2021

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. Nor can there be any guarantee that such products will be commercially successful in the future. About Sandoz.

Clinical Development 40

Clinical Development Medicine Development Production 40

Pharmaceutical Technology

SEPTEMBER 22, 2022

The current standards of care (SOCs) in OA focus on symptom management and are made up of generic pharmaceuticals, including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants, and intra-articular injections.

Marketing 147

Marketing Generic Pharmaceutical Clinical Trials Clinical Trials 147

XTalks

AUGUST 2, 2023

We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. 12) Shanghai Pharmaceuticals By: Vincent Xie, M.Sc. 2022 Revenue: Shanghai Pharmaceuticals had a revenue of 231.98 billion RMB ($34.47

Sales 98

Sales Manufacturing FDA Approval Life Science 98

FDA Law Blog

JANUARY 24, 2024

Biotechnology and Biomanufacturing; Harnessing Research and Development to Further Societal Goals.” As the report explains: This report provides a vision for harnessing research and development (R&D) advances in biotechnology and biomanufacturing to build supply chain resilience. bioeconomy.”

Manufacturing 69

Manufacturing Drugs Generic Pharmaceutical Production 69

Pharmaceutical Technology

MARCH 22, 2023

In the 1990s, generic pharmaceutical companies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. It was a money-saving strategy that was paying off until Covid-19 hit. For example, Roche and GlaxoSmithKline in the UK.

Production 263

Production Manufacturing Generic Drugs Drugs 263